MLchartDataset catalogue

Naxitamab

Term · Oncology and biomedicine · MLC-T-ONC-005695

A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children aged 1 year and older and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Naxitamab binds to a substance called GD2, which is found on some types of cancer cells. Naxitamab may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Danyelza.

Table 1. Record
IdentifierMLC-T-ONC-005695
FieldOncology and biomedicine
SynonymsDanyelza
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-005695",
  "term": "Naxitamab",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children aged 1 year and older and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Naxitamab binds to a substance called GD2, which is found on some types of cancer cells. Naxitamab may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Danyelza.",
  "synonyms": [
    "Danyelza"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/naxitamab/"
}

Record 11,632 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.